# Gilead Sciences, Inc.  Share Price Target ‘$107.03’, now 1.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc-share-price-target-107-03-now-1-7-upside-potential/4121187093
- Published: 2025-02-20T15:04:40+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) now have 27 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $126.00 and $82.00 suggesting an average analyst share
price target price of $107.03. (at the time of writing). Given that the stocks previous
close was at $105.25 this would indicate that there is a potential upside of 1.7%.
The 50 day MA is $94.49 and the 200 moving average now moves to $81.74. The market
capitalization for the company is 134.16B. The current share price for the company
is: $107.65 USD

 The potential market cap would be $136,435,099,161 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 283.29, revenue per share of $23.06
and a 11.22% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on:
